Sign in
CompletedPhase 2

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

Key facts

Who runs it
GlaxoSmithKline
Where
Bardstown, Brownsville, Charleston, Cincinnati, Cleveland, Covington, Cranberry Township, Dallas, Dickinson, Gardena, Greenville, Hastings, Haughton, Houston, Jefferson Hills, Jonesboro, Lafayette, Layton, Lexington, Los Angeles, Louisville, Madera, Mankato, McAllen, Miami, Missoula, N. Huntingdon, Nampa, New Orleans, Norfolk, Ontario, Pensacola, Pittsburgh, Richmond, Roy, Saint Augustine, Salt Lake City, South Jordan, Spartanburg, Syracuse, Tampa, and Tulsa, United StatesSee the 42 sitesAlso in 1 other country, 4 sites
Status
Completed
Phase
Phase 2
People taking part
388 people enrolled
Started
16 Jun 2022
Ended
18 Sept 2025
Type of study
Interventional, 7 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • AFX3772
  • Prevnar 13
  • Prevnar 20
Record updated
9 October 2026

Who can take part

Age
42 days to 90 days
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Participant has an LAR who understands study procedures, alternative treatments and risks involved in the study and who voluntarily agrees to participate by giving informed consent
  • Participant is a full-term (≥37 weeks gestation at birth) infant approximately 2 months of age (42 to 90 days, inclusive) at time of obtaining the informed consent
  • Participant is healthy based on the clinical judgment of the investigator following review of medical history and physical examination

Who cannot take part

  • Participant had prior administration of any pneumococcal vaccine
  • Participant has any clinically significant allergic condition or history (including anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to the first vaccination for primary immunization series
  • Participant has cochlear implant or cerebrospinal fluid leakage
  • Has received other licensed non-live vaccines within the 14 days or a licensed live virus vaccine within the 30 days prior to receipt of study vaccine
  • Participant has received immunoglobulins. Note: This does not include monoclonal antibodies, such as palivizumab or nirsevimab
  • Participant has received systemic corticosteroids (equivalent of >2 mg/kg total daily dose of prednisone or >20 mg/day for persons weighing >10 kg) for a period of more than 14 days and has not completed the treatment for at least 30 days before study vaccine. Topical, ophthalmic, and inhaled steroids are allowed
  • Participant has febrile illness (rectal temperature ≥38.1°C [100.5°F] or axillary temperature ≥37.8°C [100.0°F]) in Part 1 and Part 2 prior to the effective date of protocol amendment 4. After protocol amendment 4 becomes effective, febrile illness is defined as rectal temperature ≥38.0°C [100.4°F] or axillary temperature ≥37.5°C (99.1°F) in Part 2. Upon resolution of symptoms, participant can be rescreened
  • Participant has received any investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening
  • Participant has a known or suspected hypersensitivity to AFX3772, PCV13, PCV20 or any components of the formulations used
  • Participant has a known or suspected immunodeficiency (including autoimmune disease) or other conditions associated with immunosuppression that may require immunosuppressive drugs including but not limited to HIV infection, malignancy or organ or bone marrow transplant; In addition, the participant's biological mother has known HIV infection or known to be hepatitis B surface antigen positive
  • Participant has medical history of epilepsy or febrile convulsion
  • Participant has known neurological or cognitive behavioral disorders including clinically significant developmental disorder and related disorders
  • Participant has any active malignancy or history of malignancy
  • Participant has a history of microbiologically proven invasive disease caused by S. pneumoniae
  • Participant has a bleeding diathesis or condition associated with prolonged bleeding that would contraindicate intramuscular injection
  • Participant has any condition which, in the investigator's opinion, makes the participant unsuitable for study participation
  • Participant has functional asplenia
  • Participant weighed <2000 g at birth
  • LARs that are study personnel or their immediate dependents, family, or household members

Where in United States

Also in 1 other country, 4 sites

  • Bardstown, KentuckyHospital not named in the registry
  • Brownsville, TexasHospital not named in the registry
  • Charleston, South CarolinaHospital not named in the registry
  • Cincinnati, OhioHospital not named in the registry
  • Cleveland, OhioHospital not named in the registry
  • Covington, LouisianaHospital not named in the registry
  • Cranberry Township, PennsylvaniaHospital not named in the registry
  • Dallas, TexasHospital not named in the registry
  • Dickinson, TexasHospital not named in the registry
  • Gardena, CaliforniaHospital not named in the registry
  • Greenville, South CarolinaHospital not named in the registry
  • Hastings, NebraskaHospital not named in the registry
  • Haughton, LouisianaHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Jefferson Hills, PennsylvaniaHospital not named in the registry
  • Jonesboro, ArkansasHospital not named in the registry
  • Lafayette, ColoradoHospital not named in the registry
  • Layton, UtahHospital not named in the registry
  • Lexington, KentuckyHospital not named in the registry
  • Los Angeles, CaliforniaHospital not named in the registry
  • Louisville, KentuckyHospital not named in the registry
  • Madera, CaliforniaHospital not named in the registry
  • Mankato, MinnesotaHospital not named in the registry
  • McAllen, TexasHospital not named in the registry
  • Miami, FloridaHospital not named in the registry
  • Missoula, MontanaHospital not named in the registry
  • N. Huntingdon, PennsylvaniaHospital not named in the registry
  • Nampa, IdahoHospital not named in the registry
  • New Orleans, LouisianaHospital not named in the registry
  • Norfolk, VirginiaHospital not named in the registry
  • Ontario, CaliforniaHospital not named in the registry
  • Pensacola, FloridaHospital not named in the registry
  • Pittsburgh, PennsylvaniaHospital not named in the registry
  • Richmond, VirginiaHospital not named in the registry
  • Roy, UtahHospital not named in the registry
  • Saint Augustine, FloridaHospital not named in the registry
  • Salt Lake City, UtahHospital not named in the registry
  • South Jordan, UtahHospital not named in the registry
  • Spartanburg, South CarolinaHospital not named in the registry
  • Syracuse, New YorkHospital not named in the registry
  • Tampa, FloridaHospital not named in the registry
  • Tulsa, OklahomaHospital not named in the registry

About the trial

What the trial wants to find out

This is a Phase 2 clinical study evaluating AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of three different formulations of AFX3772 compared with Prevnar 13 (PCV13) and Prevnar 20 (PCV20).

Read full original descriptionShow less

Part 1 is the dose-escalation lead-in portion of the study, in which infants at each dose level are randomized 3:1 in sequential cohorts to receive increasing doses of AFX3772 or PCV13.

In Part 2, infants are randomized to receive either one of two dose levels of AFX3772 or PCV20.

On 31 October 2024, the study was placed on partial clinical hold by the U.S. Food and Drug Administration. The hold was not related to safety concerns in participants who had already received the study vaccines. As a result, enrollment was paused and no further doses of the investigational pneumococcal vaccine were administered. Participants who were already enrolled transitioned to the standard of care pneumococcal vaccine to complete their scheduled visits through post-dose 3 and subsequently completed study follow-up.

The 7 groups in the trial

  • Part 1: AFX3772 1 µgTreatment being tested

    AFX3772 1 µg was administered at 2, 4, and 6 months of age. Participants who did not receive a planned AFX3772 dose received PCV13 as standard of care.

    Treatment: AFX3772 and Prevnar 13

  • Part 1: AFX3772 2 µgTreatment being tested

    AFX3772 2 µg was administered at 2, 4, and 6 months of age. Participants who did not receive a planned AFX3772 dose received PCV13 as standard of care.

    Treatment: AFX3772 and Prevnar 13

  • Part 1: AFX3772 5 µgTreatment being tested

    AFX3772 5 µg was administered at 2, 4, and 6 months of age. Participants who did not receive a planned AFX3772 dose received PCV13 as standard of care.

    Treatment: AFX3772 and Prevnar 13

  • Part 1 Comparator: PCV13Existing treatment, for comparison

    PCV13 was administered at 2, 4, and 6 months of age.

    Treatment: Prevnar 13

  • Part 2: AFX3772 2 µgTreatment being tested

    AFX3772 2 µg was administered at 2, 4, and 6 months of age. Participants who did not receive a planned AFX3772 dose received PCV20 as standard of care.

    Treatment: AFX3772 and Prevnar 20

  • Part 2: AFX3772 5 µgTreatment being tested

    FX3772 5 µg was administered at 2, 4, and 6 months of age. Participants who did not receive a planned AFX3772 dose received PCV20 as standard of care.

    Treatment: AFX3772 and Prevnar 20

  • Part 2 Comparator: PCV20Existing treatment, for comparison

    PCV20 was administered at 2, 4, and 6 months of age.

    Treatment: Prevnar 20

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2, Randomized, Double-blind, Multi-dose, Dose Finding Study to Evaluate the Safety, Tolerability and Immunogenicity of AFX3772 Compared With PCVs in Healthy Infants
Record updated
9 October 2026